CA3227324A1 - Treatment of serotonin reuptake inhibitor withdrawal syndrome - Google Patents

Treatment of serotonin reuptake inhibitor withdrawal syndrome Download PDF

Info

Publication number
CA3227324A1
CA3227324A1 CA3227324A CA3227324A CA3227324A1 CA 3227324 A1 CA3227324 A1 CA 3227324A1 CA 3227324 A CA3227324 A CA 3227324A CA 3227324 A CA3227324 A CA 3227324A CA 3227324 A1 CA3227324 A1 CA 3227324A1
Authority
CA
Canada
Prior art keywords
escitalopram
gentisate
subject
days
administered
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3227324A
Other languages
English (en)
French (fr)
Inventor
Mark Hasleton
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA3227324A1 publication Critical patent/CA3227324A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Toxicology (AREA)
  • Biomedical Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Psychiatry (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Addiction (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Dermatology (AREA)
CA3227324A 2021-07-06 2022-07-06 Treatment of serotonin reuptake inhibitor withdrawal syndrome Pending CA3227324A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163218535P 2021-07-06 2021-07-06
US63/218,535 2021-07-06
PCT/IB2022/056229 WO2023281406A1 (en) 2021-07-06 2022-07-06 Treatment of serotonin reuptake inhibitor withdrawal syndrome

Publications (1)

Publication Number Publication Date
CA3227324A1 true CA3227324A1 (en) 2023-01-12

Family

ID=82942712

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3227324A Pending CA3227324A1 (en) 2021-07-06 2022-07-06 Treatment of serotonin reuptake inhibitor withdrawal syndrome

Country Status (8)

Country Link
US (1) US20240277654A1 (enExample)
EP (1) EP4366726A1 (enExample)
JP (1) JP2024529009A (enExample)
KR (1) KR20240117521A (enExample)
CN (1) CN118284414A (enExample)
AU (1) AU2022308198A1 (enExample)
CA (1) CA3227324A1 (enExample)
WO (1) WO2023281406A1 (enExample)

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7833543B2 (en) 1995-06-07 2010-11-16 Durect Corporation High viscosity liquid controlled delivery system and medical or surgical device
US6495164B1 (en) 2000-05-25 2002-12-17 Alkermes Controlled Therapeutics, Inc. I Preparation of injectable suspensions having improved injectability
US7731947B2 (en) 2003-11-17 2010-06-08 Intarcia Therapeutics, Inc. Composition and dosage form comprising an interferon particle formulation and suspending vehicle
PT1635875E (pt) 2003-06-26 2008-12-09 Psivida Inc Sistema de libertação de um fármaco com gelificação in situ
CA2553254C (en) 2004-01-12 2013-12-17 The Trustees Of The University Of Pennsylvania Long-term delivery formulations and methods of use thereof
EP1576952A1 (en) 2004-03-18 2005-09-21 OctoPlus Technologies B.V. Hydrogel microspheres with improved release profile
NL1026261C2 (nl) 2004-05-25 2005-11-28 Nanomi B V Sproei inrichting met een nozzleplaat voorzien van structuren ter bevordering van self-breakup, een nozzleplaat, alsmede werkwijzen ter vervaardiging en toepassing van een dergelijke nozzleplaat.
EP1768650B1 (en) 2004-06-04 2008-07-16 Camurus Ab Liquid depot formulations
US8852638B2 (en) 2005-09-30 2014-10-07 Durect Corporation Sustained release small molecule drug formulation
WO2007139744A2 (en) 2006-05-23 2007-12-06 Titan Pharmaceuticals, Inc. Implantable polymeric device for sustained release of buprenorphine with minimal initial burst
RU2456018C2 (ru) 2006-07-11 2012-07-20 КьюПиЭс, ЭлЭлСи Фармацевтические композиции для доставки пептидов с замедленным высвобождением
FI20070174A0 (fi) 2007-02-28 2007-02-28 Delsitech Oy Menetelmä silikakoostumusten valmistamiseksi, silikakoostumukset ja niiden käytöt
KR100805208B1 (ko) 2007-03-27 2008-02-21 주식회사 펩트론 엑센딘 함유 서방성 제제 조성물, 엑센딘 함유 서방성미립구 및 이의 제조 방법
EP2139458A4 (en) 2007-04-19 2013-01-23 Dong A Pharm Co Ltd BIODEGRADABLE MICRO BEADS COMPOSITION FOR CONTROLLED RELEASE OF GLUCOSE-CONTROLLED PEPTIDE AND FORMULATION THEREOF
BRPI0811319A2 (pt) 2007-05-25 2015-02-10 Tolmar Therapeutics Inc Composição fluida, método de formação de uma composição fluida, implante biodegrádavel formado in situ, método de formação de um implante biodegradável in situ, kit, implante e método de trataento
ES2324009B1 (es) 2007-11-23 2010-05-21 Gp Pharm S.A. Composicion farmaceutica de liberacion sostenida de somatostatina o un analogo suyo.
US20090181068A1 (en) 2008-01-14 2009-07-16 Dunn Richard L Low Viscosity Liquid Polymeric Delivery System
AU2009255675B2 (en) 2008-06-03 2014-10-09 Tolmar Therapeutics, Inc. Controlled release copolymer formulation with improved release kinetics
PL2323623T3 (pl) 2008-08-12 2017-04-28 Novartis Ag Kompozycje farmaceutyczne
AU2009301646B2 (en) 2008-10-10 2013-09-05 Polyactiva Pty Ltd Biodegradable polymer - bioactive moiety conjugates
EP2379064B1 (en) 2008-12-15 2020-02-26 Pfizer Inc. Long circulating nanoparticles for sustained release of therapeutic agents
WO2010105093A2 (en) 2009-03-12 2010-09-16 Delpor, Inc. Implantable device for long-term delivery of drugs
AU2016228315B2 (en) * 2009-09-17 2018-01-04 Bespoke Bioscience, Llc Role of n-2 hydroxy-ethyl-piperazine-n'-2-ethane sulfonic acid (hepes) in pain control and reversal of demyelinization injury
WO2011042453A1 (en) 2009-10-06 2011-04-14 Ascendis Pharma As Subcutaneous paliperidone composition
ES2699692T3 (es) 2010-01-04 2019-02-12 Mapi Pharma Ltd Sistema de depósito que comprende acetato de glatiramer
EP2343046A1 (en) 2010-01-08 2011-07-13 Nirvana's Tree House B.V. Functionalised triblock copolymers and compositions containing such polymers
SI2394663T1 (sl) 2010-05-31 2022-02-28 Laboratorios Farmaceuticos Rovi, S.A. Sestave za injicirane biološko razgradljive vsadke in situ
UA111162C2 (uk) 2010-08-04 2016-04-11 Флекшен Терап'Ютікс, Інк. Ін'єкційна композиція ацетоніду триамцинолону для лікування болю
FR2968994B1 (fr) 2010-12-17 2012-12-28 Flamel Tech Sa Procede de preparation de nanoparticules
MX347090B (es) 2010-12-29 2017-04-11 Medincell Composiciones de suministro de farmacos biodegradables.
RS60051B1 (sr) 2011-06-10 2020-04-30 Ramscor Inc Formulacije sa produženim oslobađanjem za isporuku proteina u oko i postupci njihove pripreme
EP2770983B1 (en) 2011-10-24 2017-04-19 Braeburn Pharmaceuticals, Inc. Implantable drug delivery compositions and methods of treatment thereof
RU2672596C2 (ru) 2012-01-23 2018-11-16 Аллерган, Инк. Биологически разлагаемые или биологически разрушаемые микросферы или микрочастицы длительного высвобождения, суспендированные в затвердевающем депообразующем инъекцируемом лекарственном составе
US20140323517A1 (en) 2013-04-30 2014-10-30 Heron Therapeutics, Inc. Compositions and methods for injection of a biodegradable polymer-based delivery system
RU2658004C2 (ru) 2013-06-20 2018-06-19 Фарматен С.А. Получение полилактидно-полигликолидных микрочастиц, характеризующихся сигмоидальным профилем высвобождения
AU2018349284B2 (en) * 2017-10-09 2023-11-16 428 Pharma BV. New salt and solid state forms of escitalopram

Also Published As

Publication number Publication date
JP2024529009A (ja) 2024-08-01
KR20240117521A (ko) 2024-08-01
WO2023281406A1 (en) 2023-01-12
AU2022308198A1 (en) 2024-02-01
US20240277654A1 (en) 2024-08-22
CN118284414A (zh) 2024-07-02
EP4366726A1 (en) 2024-05-15

Similar Documents

Publication Publication Date Title
US12409176B2 (en) Methods of treating acute depression
JP5992924B2 (ja) ブレクスピプラゾール又はその塩及び第二薬剤を含有する中枢神経疾患を治療するための組合せ薬剤
EP3064206B1 (en) Treatment of huntington's disease using laquinimod
WO2008156749A1 (en) Combination therapy for depression
KR20140003659A (ko) 폐경전 성욕 장애의 치료를 위한 플리반세린의 용도
CA3104811C (en) Composition comprising pramipexole and nk1-antagonists for treating depression
WO2022177718A1 (en) Use of neuroactive steroid for treatment of sexual dysfunction
TW201815385A (zh) 用以治療中樞神經系統疾病之包含苯甲酸鹽化合物及鞣酸的組合物
US20260027057A1 (en) Therapeutic formulations and uses thereof
US8664265B2 (en) Stable dosage forms of spiro and dispiro 1,2,4-trioxolane antimalarials
JP2020533415A (ja) ナルコレプシーの処置におけるガボキサドールの使用
EP4366726A1 (en) Treatment of serotonin reuptake inhibitor withdrawal syndrome
TWI864376B (zh) 焦慮症處置用組成物及處置方法
US20080058345A1 (en) Combination Therapy with Mecamylamine for the Treatment of Mood Disorders
US20240100012A1 (en) Pharmaceutical dosage form
US20070088079A1 (en) Prophylactic or therapeutic agent for sleep disorder
US20250041232A1 (en) Microspheres comprising high-dose varenicline, method for preparing same, and pharmaceutical composition comprising same
KR20250136266A (ko) 자가포식 관련 질환의 관리를 위한 약학적 조성물
KR102967223B1 (ko) 신규한 방법
AU2024204318A1 (en) Treatment of Post-Traumatic Syndrome Disorder
TW200800160A (en) Prophylactic or therapeutic agent for sleep disorder
KR20240043716A (ko) 도네페질 및 리바스티그민을 함유하는 치매 또는 인지기능 장애 예방, 개선 또는 치료용 약학적 조합물 및 이의 제조방법
WO2007034778A1 (ja) 睡眠障害予防治療剤
JP2008255058A (ja) 睡眠障害予防治療剤

Legal Events

Date Code Title Description
MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 3RD ANNIV.) - STANDARD

Year of fee payment: 3

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250627

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250627

R00 Party data change recorded

Free format text: ST27 STATUS EVENT CODE: A-1-1-R10-R00-R116 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPOINTMENT OF AGENT REQUEST

Effective date: 20260413

Free format text: ST27 STATUS EVENT CODE: A-1-1-R10-R00-R119 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REVOCATION OF AGENT REQUEST

Effective date: 20260413

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20260413